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Abstract 
 
Hepatic resection, the only treatment that offers long term survival for patients with Hepatocellular carcinoma 
(HCC), have shown significant improvement in results over the past decades. The aim of the study was to compare 
the survival between patients receiving and not receiving surgery. A retrospective cohort study measured the survival 
of newly diagnosed cases of HCC patients who underwent treatment in Selayang Hospital from 1 January 2003 till 
31 December 2006. Survival time was measured from the date of diagnosis until the subjects died or until the end of 
study period (31 December 2007). Overall survival was significantly longer in surgery group in comparison with 
non-surgery group with a median survival of 43 and 20 months, respectively (p<0.001). The following factors were 
noted to have improved survival duration with surgical resection; Child Pugh Class B patients, tumor size less or 
more than 4cm and number of nodules less than 3. Subgroup analysis showed improved survival duration with 
surgical resection among patients with Child Pugh Class B with tumor size less than 4cm or with nodule less than 3 
and patients who had less than 3 nodules, even with tumor size of less or more than 4cm. Multivariate Cox Re-
gression showed surgical intervention significantly improved survival time for overall patients (Adjusted HR: 1.5) 
while non-surgery improved survival in patients with tumor size less than 4cm (Adjusted HR: 0.4). Surgical 
resection significantly improved the survival duration in overall patients while non-surgical procedure improved 
survival if the tumor size was less than 4cm. 
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Introduction 
 
Most researchers have found out that Hepatocellular 
Carcinoma (HCC) was increasing in trend as well as 
the mortality. HCC accounts for 6% of all cancers 
worldwide and the fifth commonest cancer in the 
world. The estimated number of people who develop 
HCC is 564,000 cases per year worldwide (1). In 
Malaysia, HCC is one of the commonest malignancies 
with an age-standardised annual incidence of 2.8 cases 
per 100,000 populations (2). It accounts for 5.6% of all 
cancers and 8.1% of all cancer related death in this 
country. It is the twelfth commonest cancer in men and 
ranked eighteenth amongst women in Malaysia as 
reported by National Cancer Registries, 2002 (2). 
 
Hepatic resection, the only treatment that offers long-
term survival for patients with HCC, has shown 
significant improvement in results within past decade
 
(3-6). Although few would contest this well-
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established fact, the paradox is that no randomized 
study has clearly demonstrated the benefit of surgery 
especially in liver centre of Malaysia, Selayang 
Hospital. HCC is often associated with cirrhosis and 
the remnant hepatic functional reserve is not always 
preserved well and candidates for hepatic resection are 
limited (7-9). Recently, HCC have been often treated 
by nonsurgical therapeutic options such as transhepatic 
arterial chemoembolization (TACE), percutaneous 
ethanol injection treatment (PEI) (10), microwave 
coagulation therapy (MCT) (11) and percutaneous 
radiofrequency thermal ablation (RFA) (12). 
 
The reported 5-year overall survival for surgery ranges 
from 35% to 60%, whereas the 3-year overall survival 
for non-surgery ranges from 13% to 26% (13-14). In 
view of that, we opine that surgery gives better survival 
for HCC patients compared to non-surgery. This study 
aims to give evidence based benefit of surgery in HCC 
patients at the liver centre of Malaysia with regard to 
survival. It is hypothesized that surgery gives a better 
survival compared to non-surgery procedures.   
 
METHODS 
 
Study Design  
 
Selayang Hospital is known as liver centre of Malaysia 
in which start operated on 2000. Most of hepatobiliary 
disease was referred here for further management as 
well as HCC. This study was a retrospective cohort to 
all newly diagnosed HCC patients by CT Scan in liver 
centre, Malaysia (Selayang Hospital) from 1 January 
2003 till 31 December 2006. All patients were 
followed up until achieving the primary endpoint 
(death) or until the end of the study as on 31 December 
2007.  It was universal sampling with inclusion and 
exclusion criteria being constructed. Inclusion criteria 
were based on all newly diagnosed HCC patients with 
CT Scan from 1 January 2003 till 31 December 2006 
and exclusion criteria included multiple cancer. 
 
Sample size of 210 was based on study by Verhoef et 
al (15)
 
with power of 90%. Demographic information 
(age, gender, ethnic, alcohol intake, hepatitis status) 
and clinical variables (tumor size, number of nodules, 
Child Pugh Class, types of treatment) were obtained 
from medical records. The surgeon decided on the type 
of treatment that depended on findings of CT Scan in 
which this study only focussed on tumor size, number 
of nodules and Child Pugh Class. Small tumor, less 
nodules involved with Child Pugh class A or early B 
were considered as candidate for surgical resection.  
 
Data was collected between February to April 2009 by 
review all the variables in medical record. The CT 
Scan finding was noted in view of tumor size and 
number of nodules involved. All the patients were 
followed up for their survival status by registering 
death and via telephone.  
 
Statistical Analysis 
 
All data were collected and analyzed with statistical 
computer software (SPSS 13.0). Categorical variables 
were compared using the chi-square test and overall 
survival analyses were carried out using the Kaplan-
Meier methods. Comparisons between different groups 
were carried out using log rank test. Multivariate 
analyses for survival were carried out using Cox’s 
Regression model. Tests were deemed to be significant 
at the 0.05 levels. The survival status coded as death 
(1) and censored (0). 
 
RESULTS 
 
Demographic 
 
A total of 210 HCC patients were evaluated from 1 
January 2003 till 31 December 2006 with 123 patients 
dead and 87 being censored case. Most of HCC patients 
were aged between 40-60 years, males, Chinese ethnic, 
with no alcohol intake and positive hepatitis status as 
shown in Table 1. Out of 210 HCC patients, 114 
patients underwent surgical resection and 96 patients 
received non-surgical procedure.  The choice of surgery 
significantly depended on age group and alcohol status. 
 
Majority of HCC patients were Child Pugh Class A in 
which 65.6% underwent surgical resection while Child 
Pugh Class B and Child Pugh Class C were mostly 
received non-surgery procedures. The difference was 
significant as well as in number of nodules involved. As 
shown in Table 2, most of HCC patients who underwent 
surgical resection involved nodules less than 3(59%) 
compared to only 36.4% patients with nodules more 
than 3. Out of 210 patients, 128 patients presented with 
tumor size more than 4cm with 59.4% were having 
surgical resection. However, only 46.3% of tumor size 
less than 3cm underwent surgical resection. 
 
Survival 
 
Overall median survival time for patients having 
surgical resection was 43 months (95%CI: 31.7-54.3) 
with a 3-year and 5-year survival rate of 55% and 26%, 
respectively. It showed that surgery had a better survival 
compared to non-surgical procedures in which overall 
median survival time was only 20 months (95%CI: 
15.5-24.4) with a 3-year and 5-year survival rate of only 
23% and 13%, respectively (Table 3, Figure 1). 
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Table 1: Demographic of HCC patients 
 
Variables Total (n=210) 
Had Surgery 
p value 
Yes (n=114) No (n=96) 
Age     
<40 years old 14(6.7%) 12(85.7%) 2(14.3) 
0.02 40-60 years old 112(53.3%) 54(48.2%) 58(51.8%) 
>60 years old 84(40.0%) 48(57.1%) 36(42.9%) 
Gender     
Male 166(79%) 86(51.8%) 80(48.2%) 
0.16 
Female 44(21%) 28(63.6%) 16(36.4%) 
Ethnic     
Chinese 159(75.7%) 87(54.7%) 72(45.3%) 
0.83 Malay 42(20%) 23(54.8%) 19(45.2%) 
Indian 9(4.3%) 4(44.4%) 5(55.6%) 
Alcohol     
No 124(59%) 75(60.5) 49(39.5) 
0.03 
Yes 86(41%) 39(45.3) 47(54.7) 
Hepatitis Status     
No 49(19%) 25(62.5) 15(37.5) 
0.25 
Yes 170(81%) 89(52.4) 81(47.6) 
 
 
 
Table 2: Clinical variables of HCC patients 
 
Variables Total (n=210) 
Had Surgery 
p value 
Yes (n=114) No(n=96) 
Child Pugh 
Class 
    
A 125(59.5%) 82(65.6%) 43(34.4%) 
<0.001 B 80(38.1%) 32(40%) 48(60%) 
C 5(2.4%) 0 5(100%) 
Tumor Size     
<4cm 82(39%) 38(46.3%) 44(53.7%) 
0.064 
>4cm 128(61%) 76(59.4%) 52(40.6%) 
Number of nodules    
<3 166(79%) 98(59%) 68(41%) 
0.007 
>3 44(21%) 16(36.4%) 28(63.6%) 
 
 
Table 3 summarized the differences between HCC 
patients who underwent surgical resection or not with 
clinical variables which played an important factor 
especially before deciding the types of treatment. For 
the surgery group, the median survival time was better 
with Child Pugh Class B (25 months, 95% CI: 5.8-
44.2), tumor size less than 4cm (57 months, 95% CI: 
44.4-69.6), tumor size more than 4cm (21 months,  
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Table 3: Univariate Analysis of Survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Kaplan-Meier survival estimates by treatment 
Variables n Died Median(months) 95%CI 
1 
year 
3 
year 
5 
year 
p value 
Overall         
Surgery 114 54 43 31.7-54.3 74 55 26 
<0.0001 
No Surgery 96 69 20 15.5-24.4 61 23 13 
Child Pugh Class A         
Surgery 82 34 57 39.2-74.7 75 61 35 
0.22 
No Surgery 43 22 26 19.9-32.0 86 37 37 
Child Pugh Class B         
Surgery 32 20 25 5.8-44.2 65 47 23 
0.04 
No Surgery 48 42 13 10.1-15.9 76 14 0.4 
HCC <4cm         
Surgery 37 11 57 44.4-69.6 88 84 30 
0.003 
No Surgery 41 24 25 17.7-32.3 73 38 25 
HCC >4cm         
Surgery 77 43 21 11.4-30.6 66 39 24 
0.005 
No Surgery 55 45 15 9.6-18.3 48 0.7 0.7 
Nodule <3         
Surgery 98 40 57 38.9-75.1 76 62 34 
<0.005 
No Surgery 68 46 21 15.1-26.8 69 27 13 
Nodule >3         
Surgery 16 14 12 2.5-21.5 56 19  
0.632 
No Surgery 28 23 12 9.5-14.5 60 15 13 
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95% CI: 11.4-30.6) and number of nodules involved 
less than 3(57 months, 95% CI: 38.9-75.1)  
 
Subgroup analysis of survival showed that HCC 
patients of Child Pugh Class B with tumor size less 
than 4cm or nodule less than 3, the surgical approach 
gave benefit of survival as well as in group of nodule 
less than 3 with tumor size less or more than 4cm 
(Table 4). 
 
Table 4 summarized the prediction model in survival 
of HCC patients according to overall patients and 
tumor size. Negative prognostic factors for overall 
HCC patients were non surgery (aHR: 1.5), Child 
Pugh Class B(aHR:2.0), Child Pugh Class C(aHR: 3.0) 
and tumor size more or same than 4cm(aHR:2.3). In 
view of HCC patients with tumor size less than 4cm, 
the non surgery procedure gave benefit of HCC 
patients survival (aHR: 0.4) while for tumor size more 
or same with 4cm, both of procedure did not benefit 
off HCC patients survival. 
 
Discussion 
 
Nowadays, the management of HCC offers many 
treatment options in relation to the tumor stage (16). 
Among these, liver transplantation has the best results in 
terms of overall survival (17). However, this procedure 
was not performed in Malaysia because of organ 
shortage. Liver surgery for HCC has improved its 
results in patients during the last decades with mortality 
lower than 5% in most series (18).  The availability of 
non-surgery approach makes treatment options wider 
and some will benefit on survival of HCC patients. 
 
Surgical resection was considered the treatment of 
choice for patients with absent of alcohol intake, Child 
Pugh Class A and number of nodules less than 3. The 
surgeon may have their own reason before deciding 
the types of treatment in which majority study agreed 
that Child Pugh Class A and less nodules involved 
should be offered for surgical resection. The absence 
of alcohol intake in HCC patients will clarifies the 
liver status, should it be good with no cirrhosis. 
Therefore surgical may not be offer to this patients and 
non-surgery treatment will be the choice. 
  
As agreed upon by many researchers (19, 20), surgery 
gives a better survival compared to non-surgery 
procedure with median 43 months and 20 months, 
respectively. Few studies did not opine (21, 22) in 
which the sample size was too small, compared to this 
study which agreed with surgery give a better survival. 
Surgical resection will remove the entire cancer cell 
while non-surgery procedure needs a repetition of 
procedure. The time taken longer in non-surgery 
procedure explained the survival duration become 
shorter besides of other factors such as cirrhosis or late 
stage of cancer. 
 
There was no difference of survival in Child Pugh 
Class A in view of treatment. However, for Child Pugh 
Class B, surgery gave a prolonged survival with 
median 20 months. Tumor size and number of nodules 
involved, plays an important deciding factor of types 
of treatment. As we observed in this study, it was 
shown that patients who had tumor size of less or more 
than 4cm and nodules involved less than 3, had a good 
survival with surgery procedure (23). It explained that 
multiple nodules involved will make surgery difficult 
and non-surgery approach will benefit the survival. 
However, the difference was not significant. 
 
Subgroup analysis showed that HCC patients of Child 
Pugh Class B with tumor size less than 4cm or nodules 
less than 3 gave a better survival with surgical 
resection. Good clinical stage contributed to a better 
survival with surgery as shown by Ari et al (2000) 
(13). The size does not matter in survival of HCC 
patients but with fewer nodules involvement, there 
was a longer duration of survival (24). 
 
The prediction model after controlling other factors 
proved that for overall HCC patients, surgery gave 
longer duration of survival by 1.5 times compared to 
non-surgery procedure (25). If patients had tumor size 
less than 4cm, non-surgery procedure produced benefit 
of survival by 0.4 times compared to surgery in 
univariate and multivariate analysis. However, for 
patients who had tumor size more or same than 4cm, 
the comparison of treatment did not reach statistical 
significance in multivariate analysis. 
 
Besides surgery, the prediction model for overall 
patients also showed that good clinical stage of HCC 
(Child Pugh Class A, small tumor, less nodules 
involved)  gives a better prognostic factor as majority 
of studies reported the same findings. There is no 
argument about this prediction model as most studies 
in the past decades and current study agreed on this 
aspect
 
(20, 21, 25). Therefore, in Malaysian people 
with HCC, we also may apply this prediction towards 
a better survival. If the patients comes with tumor size 
less than 4cm, the non-surgery procedure and Child 
Pugh Class A will give improvement in duration of 
survival as we observe in Table 5. However, if tumor 
size is more or equal to 4cm, the choice of surgery or 
non-surgery will not make difference in survival 
outcome but Child Pugh Class A and involvement of 
less nodules will give a better survival. 
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Table 4: Subgroup analysis of HCC patient’s survival 
Variables n Median(months) 95%CI p value 
Child Pugh Class A & HCC <4cm     
Surgery 26 57 35.16-78.84 
0.506 
No Surgery 21 44*means 34.80-53.95 
Child Pugh Class A & HCC ≥4cm     
Surgery 56 27 0.09-53.90 
0.074 
No Surgery 22 20 13.52-26.48 
Child Pugh Class B & HCC <4cm     
Surgery 11 57  
0.005 
No Surgery 18 14 10.16-17.83 
Child Pugh Class B & HCC ≥4cm     
Surgery 21 14 4.27-23.73 
0.703 
No Surgery 30 12 7.71-16.30 
Child Pugh Class A & Nodule <3     
Surgery 72 58 31.08-84.91 
0.261 
No Surgery 33 29 24.98-33.02 
Child Pugh Class A & Nodule ≥3     
Surgery 10 5 3.54-6.46 
0.452 
No Surgery 10 6 0.0-29.24 
Child Pugh Class B & Nodule <3     
Surgery 26 25 3.40-46.60 
0.035 
No Surgery 31 14 8.67-19.33 
Child Pugh Class B & Nodule ≥3     
Surgery 6 12 0.0-39.85 
0.509 
No Surgery 17 12 10.11-13.89 
HCC <4cm & Nodule <3     
Surgery 34 57 35.31-78.70 
0.014 
No Surgery 32 29 22.08-35.91 
HCC <4cm & Nodule ≥3     
Surgery 3 57  
0.298 
No Surgery 9 12 6.76-17.24 
HCC ≥4cm & Nodule <3     
Surgery 64 27 0.0-55.72 
0.002 
No Surgery 36 16 8.36-23.64 
HCC ≥4cm & Nodule ≥3     
Surgery 13 5 3.33-6.67 
0.369 
No Surgery 19 12 7.7-16.27 
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Table 5: Predictor model for HCC patient’s survival 
 
 
Variables 
Simple Cox Regression Multiple Cox Regression* 
β 95%CI Crude HR β 95%CI 
Adjusted 
HR 
Overall   
Non-Surgery vs Surgery(96 vs 114) -0.65 0.36-0.75 0.52 0.4 1.03-2.25 1.52 
Child B vs A(80 vs 125) 0.84 1.61-3.33 2.31 0.7 1.30-2.82 1.91 
Child C vs A(5 vs 125) 1.46 1.73-10.85 4.33 1.1 1.19-7.94 3.08 
HCC <4cm vs HCC ≥4cm(128 vs 82) 0.81 1.52-3.33 2.25 0.8 1.52-3.36 2.26 
Nodule < 3 vs Nodule ≥ 3(44 vs 166) 0.84 1.57-3.40 2.31 0.4 0.97-2.27 1.49 
HCC < 4cm(n=78)  
Non-Surgery vs  Surgery(37 vs 41) -1.06 0.16-0.73 0.35 -0.9 0.18-0.83 0.39 
Child B vs A(29 vs 47) -2.19 0.02-0.51 0.11 1.1 1.48-6.33 3.06 
Child C vs A(2 vs 47) -0.02 0.08-1.57 0.36 1.8 1.27-27.79 5.96 
Nodule < 3 vs Nodule ≥ 3(66 vs 16) -0.92 0.18-0.89 0.4 0.6 0.75-4.64 1.87 
HCC ≥ 4cm(n=132)  
Non-Surgery vs Surgery(77 vs 55) 0.57 1.17-2.69 1.78 0.3 0.81-2.07 1.3 
Child B vs A(51 vs 78) 0.68 1.29-3.02 1.97 0.5 1.09-2.68 1.71 
Child C vs A(3 vs 78) 1.12 0.94-9.95 3.06 1.2 1.01-10.74 3.3 
Nodule < 3 vs Nodule ≥ 3(100 vs 32) -0.65 1.23-2.97 1.92 0.5 1.02-2.63 1.64 
*Backward stepwise Cox proportional hazards regression applied. Log-minus-log plot and hazard function plot were 
applied to check the model assumption. 
 
 
The choice of treatment depends on the surgeon 
expectation of the variety. Therefore, it is our 
limitation in looking into the different type of 
treatment and the survival of HCC patients. The choice 
of treatment sometimes not only depends on the tumor 
size, nodules involved or Child Pugh Class only but 
other factors such as co-morbidity, cirrhosis, fibrosis, 
vascular invasion which contributes to poor survival or 
when the surgical procedure cannot be performed. 
However, this study findings will give a view of 
Malaysian prognostic factor of HCC patients and as a 
pilot study for future research in survival of HCC 
patients as not much study done on survival. 
 
As in conclusion, surgery will remain a best option in 
HCC patients for a better survival but for small HCC, 
non-surgery approach also will benefit on the survival. 
Therefore, an expert opinion from the Surgeon 
whether to perform surgery or not, should consider the 
prediction model for a longer survival in HCC 
patients. Keeping in mind, the public health view, the 
3-step prevention should be more emphasized in view 
of education, promotion, early diagnosis, early 
treatment as early stage of HCC will improve the 
survival. These findings will help the Surgeon to 
choose the type of treatment depending on Child Pugh 
Class, tumor size and number of nodules involved. 
The effort should be made to ensure that every patient 
receives an appropriate treatment. 
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